{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 470620242
| type              = mab
| image             = 
| alt               = 
| mab_type          = mab
| source            = u
| target            = [[CD137]]
| tradename         =  
| Drugs.com         =
| MedlinePlus       =
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number        = 934823-49-1
| ATC_prefix        = none
| ATC_suffix        = 
| PubChem           = 
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank          =
| KEGG = D09984
| C=6502 | H=9972 | N=1712 | O=2030 | S=44
| molecular_weight = 145.8 kg/mol
}}

'''Urelumab''' ('''BMS-663513''' or anti-4-1BB antibody) is a fully human IgG4 monoclonal antibody developed by [[Bristol-Myers Squibb]] for the treatment of cancer and solid tumors.<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Urelumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/urelumab.pdf}}</ref>

Urelumab targets the extracellular domain of [[CD137]].<ref>http://web.stanford.edu/~sdutt/PDF/2015_SD_yonezawa.pdf</ref> It specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a [[cytotoxic T cell]] response, against tumor cells.<ref>{{cite web|title= Urelumab|publisher=[[National Cancer Institute]]|url=http://www.cancer.gov/drugdictionary?cdrid=489120}}</ref>

The first phase I trial began in 2006 and final results were published in 2015.<ref>https://clinicaltrials.gov/ct2/show/NCT00309023?term=NCT00309023&rank=1</ref>

Current clinical trials combine urelumab with chemotherapy (NCT00351325), chemoradiation (NCT00461110), ipilimumab (NCT00803374), rituximab (NCT01775631, NCT02420938), cetuximab (NCT02110082), and elotuzumab
(NCT02252263), nivolumab (NCT02253992) for metastatic solid tumors, NSCLC, melanoma, B-cell non-Hodgkin lymphoma, colorectal cancer, and multiple myeloma. A biomarker study using CyTOF is also underway.<ref>http://web.stanford.edu/~sdutt/PDF/2015_SD_yonezawa.pdf</ref>

==References==
<references/>

{{Monoclonals for immune system}}
{{Cytokine receptor modulators}}

[[Category:Bristol-Myers Squibb]]
[[Category:Monoclonal antibodies]]
[[Category:Experimental cancer drugs]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}